References
Engl J Med. 2014 May 15;370(20):1889-98.
11. Afdhal N, Reddy KR, Nelson DR, et al for the ION-2 Investigators.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1
infection. N Engl J Med. 2014 Apr 17;370(16):1483-93.
12. Kowdley KV, Gordon SC, Reddy KR, et al for the ION-3 Investigators.
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without
cirrhosis. N Engl J Med. 2014 May 15;370(20):1879-88.
13. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al for the
AI444040 Study Group. Daclatasvir plus sofosbuvir for previously
treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan
16;370(3):211-21.
14. Bristol-Myers Squibb. UNITY 1: A Study of an Investigational
Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) +
BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct
Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic
Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic
Subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National
Library of Medicine (US). 2000- [cited 2014 Jun 11]. Available from:
http://clinicaltrials.gov/ct2/show/NCT01979939. NLM Identifier:
NCT01979939. Accessed June 11, 2014.
15. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and
dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med.
2014 May 22;370(21):1973-82.
16. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and
dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May
22;370(21):1983-92.
17. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014
Apr 24;370(17):1594-603.
18. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with
ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med.
2014 Apr 24;370(17):1604-14.
23